A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
- 1 January 1998
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 20 (1), 182-195
- https://doi.org/10.1016/s0149-2918(98)80045-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.American Journal of Health-System Pharmacy, 1997
- Prevention of Venous Thromboembolism after Knee ArthroplastyAnnals of Internal Medicine, 1996
- Prevention of Venous ThromboembolismChest, 1995
- Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgeryArchives of Internal Medicine, 1995
- Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgeryBritish Journal of Surgery, 1994
- Prevention of Deep-Vein Thrombosis following Total Hip Replacement Surgery with Enoxaparin versus Unfractionated Heparin: A Pharmacoeconomic EvaluationAnnals of Pharmacotherapy, 1994
- Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.Journal of Bone and Joint Surgery, 1994
- A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee ImplantationNew England Journal of Medicine, 1993
- Prevention of Deep Vein Thrombosis after Elective Hip SurgeryAnnals of Internal Medicine, 1991